share_log

HC Wainwright & Co. Reiterates Buy on Talaris Therapeutics, Maintains $12 Price Target

Benzinga Real-time News ·  Jan 30, 2023 06:12

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Talaris Therapeutics (NASDAQ:TALS) with a Buy and maintains $12 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment